Cargando…
Cost-Effectiveness of Glucosamine in Osteoarthritis Treatment: A Systematic Review
Osteoarthritis (OA) is a chronic condition that most frequently affects older adults. It is currently the most common disability. The cost of treating an aging population places pressure on the healthcare budget. As a result, it is imperative to evaluate medicines’ cost-effectiveness and, accordingl...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454215/ https://www.ncbi.nlm.nih.gov/pubmed/37628537 http://dx.doi.org/10.3390/healthcare11162340 |
_version_ | 1785096134962708480 |
---|---|
author | Vo, Nam Xuan Le, Ngan Nguyen Hoang Chu, Trinh Dang Phuong Pham, Huong Lai Dinh, Khang Xuan An Che, Uyen Thi Thuc Ngo, Thanh Thi Thanh Bui, Tien Thuy |
author_facet | Vo, Nam Xuan Le, Ngan Nguyen Hoang Chu, Trinh Dang Phuong Pham, Huong Lai Dinh, Khang Xuan An Che, Uyen Thi Thuc Ngo, Thanh Thi Thanh Bui, Tien Thuy |
author_sort | Vo, Nam Xuan |
collection | PubMed |
description | Osteoarthritis (OA) is a chronic condition that most frequently affects older adults. It is currently the most common disability. The cost of treating an aging population places pressure on the healthcare budget. As a result, it is imperative to evaluate medicines’ cost-effectiveness and, accordingly, their influence on health resource allocation. Our study aims to summarize the cost and outcome of utilizing glucosamine in OA treatment. Databases like Medline, Cochrane, and Scopus were searched as part of the identification process up until April 2023. Our primary inclusion criteria centered on the economic evaluation of glucosamine in OA treatments, providing an incremental cost-effectiveness ratio (ICER). The Quality of Health Economic Studies (QHES) instrument was applied to grade the quality of the studies. Seven qualified studies that discussed the cost-effectiveness of glucosamine with or without other formulations were selected. All of them demonstrated that glucosamine was cost-effective. There was an increase in quality-adjusted life years (QALYs) when incorporating glucosamine in conventional care. Moreover, patented crystalline glucosamine sulfate (pCGS) was more cost-effective than the other formulations of glucosamine (OFG). Overall, utilizing pCGS was more beneficial than using OFG in terms both of cost and quality of life. |
format | Online Article Text |
id | pubmed-10454215 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104542152023-08-26 Cost-Effectiveness of Glucosamine in Osteoarthritis Treatment: A Systematic Review Vo, Nam Xuan Le, Ngan Nguyen Hoang Chu, Trinh Dang Phuong Pham, Huong Lai Dinh, Khang Xuan An Che, Uyen Thi Thuc Ngo, Thanh Thi Thanh Bui, Tien Thuy Healthcare (Basel) Review Osteoarthritis (OA) is a chronic condition that most frequently affects older adults. It is currently the most common disability. The cost of treating an aging population places pressure on the healthcare budget. As a result, it is imperative to evaluate medicines’ cost-effectiveness and, accordingly, their influence on health resource allocation. Our study aims to summarize the cost and outcome of utilizing glucosamine in OA treatment. Databases like Medline, Cochrane, and Scopus were searched as part of the identification process up until April 2023. Our primary inclusion criteria centered on the economic evaluation of glucosamine in OA treatments, providing an incremental cost-effectiveness ratio (ICER). The Quality of Health Economic Studies (QHES) instrument was applied to grade the quality of the studies. Seven qualified studies that discussed the cost-effectiveness of glucosamine with or without other formulations were selected. All of them demonstrated that glucosamine was cost-effective. There was an increase in quality-adjusted life years (QALYs) when incorporating glucosamine in conventional care. Moreover, patented crystalline glucosamine sulfate (pCGS) was more cost-effective than the other formulations of glucosamine (OFG). Overall, utilizing pCGS was more beneficial than using OFG in terms both of cost and quality of life. MDPI 2023-08-18 /pmc/articles/PMC10454215/ /pubmed/37628537 http://dx.doi.org/10.3390/healthcare11162340 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Vo, Nam Xuan Le, Ngan Nguyen Hoang Chu, Trinh Dang Phuong Pham, Huong Lai Dinh, Khang Xuan An Che, Uyen Thi Thuc Ngo, Thanh Thi Thanh Bui, Tien Thuy Cost-Effectiveness of Glucosamine in Osteoarthritis Treatment: A Systematic Review |
title | Cost-Effectiveness of Glucosamine in Osteoarthritis Treatment: A Systematic Review |
title_full | Cost-Effectiveness of Glucosamine in Osteoarthritis Treatment: A Systematic Review |
title_fullStr | Cost-Effectiveness of Glucosamine in Osteoarthritis Treatment: A Systematic Review |
title_full_unstemmed | Cost-Effectiveness of Glucosamine in Osteoarthritis Treatment: A Systematic Review |
title_short | Cost-Effectiveness of Glucosamine in Osteoarthritis Treatment: A Systematic Review |
title_sort | cost-effectiveness of glucosamine in osteoarthritis treatment: a systematic review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454215/ https://www.ncbi.nlm.nih.gov/pubmed/37628537 http://dx.doi.org/10.3390/healthcare11162340 |
work_keys_str_mv | AT vonamxuan costeffectivenessofglucosamineinosteoarthritistreatmentasystematicreview AT lengannguyenhoang costeffectivenessofglucosamineinosteoarthritistreatmentasystematicreview AT chutrinhdangphuong costeffectivenessofglucosamineinosteoarthritistreatmentasystematicreview AT phamhuonglai costeffectivenessofglucosamineinosteoarthritistreatmentasystematicreview AT dinhkhangxuanan costeffectivenessofglucosamineinosteoarthritistreatmentasystematicreview AT cheuyenthithuc costeffectivenessofglucosamineinosteoarthritistreatmentasystematicreview AT ngothanhthithanh costeffectivenessofglucosamineinosteoarthritistreatmentasystematicreview AT buitienthuy costeffectivenessofglucosamineinosteoarthritistreatmentasystematicreview |